FDA OKs Old Chemo-vitamin for an Ultra-rare Brain Disorder

With input from CNBC, NBC News, the Hill, CNN, Politico, the Washington Post, and Forbes.

The Food and Drug Administration has quietly approved leucovorin — a decades-old prescription form of vitamin B9 — as the first FDA-cleared treatment for a tiny genetic condition that starves the brain of folate. But make no mistake: this isn’t the big breakthrough for autism that some White House officials hinted at last year.

The short version: the agency signed off on the drug for people (kids and adults) with cerebral folate deficiency from confirmed FOLR1 variants — an ultra-rare disorder that shows up in early childhood with severe developmental delays, seizures and movement problems. The decision was driven not by a new randomized trial, but by a careful, systematic review of case reports and mechanistic evidence that reviewers felt showed dramatic benefit in this tiny group.

Back in September, the Trump administration put the drug in the spotlight, with President Donald Trump and HHS leaders suggesting leucovorin might help many children with autism. That public push led to a wave of prescriptions and a scramble at pharmacies — parents desperate for options clamored for the drug.

But agency reviewers took a different view. FDA officials said they initially cast a wide net, looking at leucovorin for autism more broadly, then narrowed their focus when the clearest, highest-quality signals pointed to the rare genetic form of cerebral folate deficiency. The agency concluded the literature around that specific, genetically defined group showed the largest, most convincing treatment effects — enough to support approval even though the data came from observational case series rather than large randomized trials.

The label expansion applies to leucovorin — including generic formulations and the old branded product Wellcovorin — for patients with confirmed CFD tied to FOLR1 defects. The disease is vanishingly rare: the National Organization for Rare Disorders and the literature estimate it affects roughly 1 in a million people, with fewer than a few dozen documented cases historically.

That rarity is the FDA’s main justification for using non-randomized evidence: reviewers said the responses reported in case series were sometimes so large — children becoming seizure-free or dramatically improving developmentally — that a placebo-controlled trial would be hard to justify ethically or logistically.

Families who heard the White House framing of leucovorin as an autism therapy have been frustrated by the agency’s narrower, science-driven outcome. Prescription rates shot up after last fall’s news: a paper in The Lancet reported a sharp increase in pediatric prescriptions in the months following the White House announcement, and pharmacists flagged spot shortages.

Parents say the messaging from the podium created hope — and headaches. Meagan Meagan Johnson, who spent weeks hunting down the drug for her toddler, told reporters she feels hurt and uncertain now that the approval is limited to a genetic condition that probably doesn’t apply to most autistic kids.

“I’m frustrated with the administration,” she said. “I feel like I just fought really hard — now what?”

Autism researchers and physicians pushed back on the broad claims from last fall. Alycia Alycia Halladay of the Autism Science Foundation said the FDA’s update is “1,000% different” from the White House rhetoric — and urged careful, controlled studies to figure out if any subsets of autistic children might benefit.

David David Mandell, who studies services for autistic kids, called the mixed messaging “terrible for families,” arguing that parents deserve clearer, evidence-based guidance rather than podium promises. And emergency physician Jeremy Jeremy Faust pointed out that the levers of public influence matter: when leaders make claims about treatments, people act — sometimes before the science is ready.

Some experts noted that clinicians had been prescribing leucovorin off-label for years in a few cases, often informed by small trials outside the US — but caution remains. One of the larger cited randomized trials was retracted after data problems, and official guidance (from groups such as the American Academy of Pediatrics) says the evidence for autism is limited and that larger, rigorous trials are needed.

The FDA said it’s talking to manufacturers about ramping up production if demand keeps rising, and urged companies to step in to prevent shortages. The branded version of the drug was originally marketed by GlaxoSmithKline but the company stopped selling it decades ago; GSK has said it doesn’t plan to relaunch the product itself.

Outside the rare-disease community, the approval is unlikely to change everyday practice for most autistic children. Clinicians can still prescribe drugs off-label, but the agency’s decision is a clear signal: the strongest evidence supports use only in genetically confirmed CFD-FOLR1 patients — not as a broad autism treatment.

I. David I. David Goldman, who has studied this ultra-rare condition, stressed that there’s little overlap between the genetic form of cerebral folate deficiency and the broader autism population.

“It’s good to set the record straight,” he said, while also acknowledging the real human toll of mixed messages.

For parents who felt relief after giving the drug to their child, that reality can be hard to reconcile with a narrower regulatory verdict.

The agency cleared an important therapy for a vanishingly rare, genetically defined brain disorder. But the long arc — from White House headlines to nuanced regulatory review — is a reminder that hopeful headlines and careful science aren’t always the same thing.